01 Transition Toward ADC and Targeted Therapy Manufacturing The increasing development of antibody-drug conjugates and targeted oncology therapies is driving demand for specialized high potency API contract manufacturing services. Pharmaceutical companies are shifting from conventional drug production to outsourcing highly potent compound manufacturing to access advanced containment technologies and regulatory expertise. This transition is expanding the role of contract manufacturers in supporting complex drug pipelines while reducing capital investment requirements. For example, Lonza has expanded its high potency manufacturing capabilities to support the growing global biologics market.
02 Expansion of Integrated End-to-End CDMO Service Models Pharmaceutical companies are increasingly preferring contract manufacturers that offer integrated services from process development and analytical testing to commercial-scale manufacturing. This transition is reducing vendor complexity, accelerating development timelines, and improving regulatory coordination across the product lifecycle. As a result, contract manufacturers are investing in comprehensive service platforms to strengthen long-term partnerships with innovator and biotech companies. For example, Cambrex provides end-to-end high potency API development and manufacturing services across multiple global facilities.
01 The high potency API contract manufacturing market is witnessing strong investment activity driven by the expanding oncology drug pipeline, increasing outsourcing, and growing demand for specialized manufacturing capabilities. In 2025, MilliporeSigma announced a USD 70 million investment to expand its high potency active pharmaceutical ingredient (HPAPI) manufacturing facility in Verona, Wisconsin, US. The investment will increase production capacity for highly potent compounds, including payloads and strengthen support for global biopharmaceutical customers.
01 The high potency API contract manufacturing market has direct exposure to supply chain disruptions due to its dependence on specialized raw materials, advanced containment equipment, and globally distributed manufacturing networks. Interruptions in the supply of critical intermediates, regulatory delays, and logistics constraints can affect production schedules, increase operational costs, and extend delivery timelines. The market is expected to witness a capacity-constrained recovery, supported by expanding manufacturing capacity, strengthened supplier networks, and continued investments in localized production capabilities.
01 Oncology Drug Development and Increasing Patent Expiration Drives Market The increasing incidence of cancer and the growing development of targeted oncology therapies are driving demand for high potency API contract manufacturing services. Modern cancer treatments require highly potent cytotoxic payloads that must be manufactured in specialized high containment facilities under strict regulatory controls. Since establishing such infrastructure involves significant capital investment and technical expertise, many pharmaceutical and biotechnology companies outsource production to specialized contract manufacturers. This outsourcing trend is increasing demand for HPAPI manufacturing capacity while enabling faster clinical development and commercialization of innovative therapies.The loss of exclusivity for several blockbuster oncology medicines is creating significant demand for High Potency API contract manufacturing as generic and biosimilar developers accelerate product development. Manufacturing HPAPIs requires advanced containment systems, validated production processes, and regulatory expertise, making outsourcing a commercially viable option for companies entering post-patent markets. This trend is increasing demand for specialized CDMOs capable of rapidly scaling commercial production while meeting global quality standards. For example, following the loss of exclusivity of Revlimid (lenalidomide) in major markets, multiple generic manufacturers, including Dr. Reddy's Laboratories, Natco Pharma, Cipla, and Teva, expanded production to launch generic versions under licensing and settlement agreements. The increased requirement for manufacturing highly potent APIs has strengthened demand for specialized HPAPI contract manufacturing capacity across regulated markets.
01 Complex Technology Transfer and Limited Availability of Specialized Containment Expertise Restrain Market Expansion Technology transfer for highly potent APIs involves the accurate replication of manufacturing processes, analytical methods, containment protocols, and quality controls from development to commercial-scale production. Even minor process variations can affect product quality, regulatory compliance, and operator safety, requiring extensive validation and documentation before commercial manufacturing begins.High potency API manufacturing requires highly trained personnel with expertise in containment engineering, toxicology, process development, occupational safety, and regulatory compliance. The global shortage of professionals with these specialized skills makes it difficult for contract manufacturers to expand operations and onboard new projects efficiently.
01 GLP-1 & Peptide Therapeutics and Expansion of Radiopharmaceutical Manufacturing Offer Growth Opportunities to Market Players The rapid expansion of GLP-1 receptor agonists and next-generation peptide therapeutics is creating significant growth opportunities for High Potency API contract manufacturers with specialized peptide synthesis and high-containment capabilities. As pharmaceutical companies scale production to meet increasing global demand, outsourcing partners with integrated development and commercial manufacturing expertise will gain a competitive advantage. This opportunity is particularly beneficial for specialized CDMOs investing in large-scale peptide manufacturing infrastructure. For example, CordenPharma and Bachem are expanding peptide production capacity to support the growing pipeline of obesity and metabolic disease therapies.The rapid development of targeted radiopharmaceutical therapies is creating new opportunities for High Potency API contract manufacturers with expertise in handling highly potent compounds under stringent containment conditions. As pharmaceutical companies expand pipelines for precision cancer treatments, demand is increasing for CDMOs capable of manufacturing cytotoxic precursors and specialized intermediates. This opportunity particularly benefits manufacturers investing in high-containment infrastructure and integrated development capabilities.
01 Need for Highly Specialized Raw Materials and Long-Term Manufacturing Contracts Hinder Growth The availability of complex cytotoxic intermediates, linker molecules, and other specialized raw materials remains limited, creating procurement challenges for HPAPI manufacturers. Supply disruptions can delay production schedules and commercial launches, particularly for oncology therapies requiring highly specific inputs. The rapid increase in antibody drug conjugate development has intensified demand for specialized linker payload components, creating supply constraints.The increasing number of specialized CDMOs has intensified competition for long-term HPAPI manufacturing contracts. Pharmaceutical companies evaluate contract manufacturers based on technical expertise, regulatory history, containment capabilities, pricing, and project timelines, making contract awards highly competitive. This puts continuous pressure on CDMOs to invest in new technologies and capacity while facing uncertainty over future project pipelines, limiting sustainable revenue growth.
June 2026 Lonza announced the expansion of its HPAPI payload-linker manufacturing capacity in Visp, Switzerland.
November 2025 Piramal Pharma Solutions formalized a partnership with IntoCell to expand its payload-linker platform and bioconjugation capabilities.
August 2025 Cambrex expanded its peptide manufacturing capabilities at its Waltham, Massachusetts facility.